{
    "Symbol": "ATHE",
    "AssetType": "Common Stock",
    "Name": "Alterity Therapeutics Ltd",
    "Description": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.",
    "CIK": "1131343",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "LEVEL 3, 460 BOURKE STREET, MELBOURNE, AU",
    "OfficialSite": "https://alteritytherapeutics.com",
    "FiscalYearEnd": "June",
    "LatestQuarter": "2024-12-31",
    "MarketCapitalization": "33980800",
    "EBITDA": "-20493620",
    "PERatio": "None",
    "PEGRatio": "None",
    "BookValue": "0.001",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-1.51",
    "RevenuePerShareTTM": "0.6",
    "ProfitMargin": "0",
    "OperatingMarginTTM": "-4.697",
    "ReturnOnAssetsTTM": "-0.784",
    "ReturnOnEquityTTM": "-1.558",
    "RevenueTTM": "3724500",
    "GrossProfitTTM": "3543600",
    "DilutedEPSTTM": "-1.51",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "-0.155",
    "AnalystTargetPrice": "11",
    "AnalystRatingStrongBuy": "1",
    "AnalystRatingBuy": "1",
    "AnalystRatingHold": "0",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "9.12",
    "PriceToBookRatio": "6.95",
    "EVToRevenue": "113.99",
    "EVToEBITDA": "0.755",
    "Beta": "0.479",
    "52WeekHigh": "5.87",
    "52WeekLow": "1.001",
    "50DayMovingAverage": "3.856",
    "200DayMovingAverage": "2.244",
    "SharesOutstanding": "10685800",
    "DividendDate": "None",
    "ExDividendDate": "None"
}